Shares of biotech stock Alkermes were falling into the red on Monday after the Food and Drug Administration said it would not review the company’s depression drug. Shares of the stock dropped over 20% and hit its lowest level in 18 months on the news. The FDA has said that the biotech company still needs … Continue reading “Alkermes Shares Collapse as FDA Refuses to Review its MLajor Depressive Disorder Drug”
